Validation of GATE 6.1 for targeted radiotherapy of metastic melanoma using 131I-labeled benzamide - IN2P3 - Institut national de physique nucléaire et de physique des particules Accéder directement au contenu
Communication Dans Un Congrès Année : 2012

Validation of GATE 6.1 for targeted radiotherapy of metastic melanoma using 131I-labeled benzamide

Résumé

The GATE 6.1 Monte Carlo simulation platform based on the GEANT4 toolkit is in constant improvement for dosimetric calculations. Here, we explore its use for calculating internal absorbed dose distribution in mice for the treatment of malignant melanoma after injection of a new specific radiopharmaceutical labeled with iodine 131. We estimate the dosimetric accuracy of GATE 6.1, by calculating first S values and by comparing them and absorbed doses to organswith EGSnrc for a digital mouse phantom and a CT scan based mouse phantom.
Fichier principal
Vignette du fichier
Perrot_MCTP2012.pdf (232.25 Ko) Télécharger le fichier
Origine : Fichiers produits par l'(les) auteur(s)
Loading...

Dates et versions

in2p3-00703187 , version 1 (01-06-2012)

Identifiants

  • HAL Id : in2p3-00703187 , version 1

Citer

Y. Perrot, L. Maigne, Vincent Breton, D. Donnarieix. Validation of GATE 6.1 for targeted radiotherapy of metastic melanoma using 131I-labeled benzamide. Third European Workshop on Monte Carlo Treatment Planning, May 2012, Seville, Spain. 5 p. ⟨in2p3-00703187⟩
77 Consultations
134 Téléchargements

Partager

Gmail Facebook X LinkedIn More